Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Three cholesterol drugs better than two for diabetics?

NCT ID NCT07255820

Disease control Sponsor: Bahria University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests whether taking three cholesterol-lowering drugs together works better than taking two in people with type 2 diabetes and high LDL cholesterol. 126 adults aged 35-60 will be split into three groups: one gets rosuvastatin plus ezetimibe, another gets bempedoic acid plus ezetimibe, and the third gets all three drugs. The goal is to see which combination lowers LDL cholesterol most safely over 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rosuvastatin, Ezetimibe, Bempedoic Acid
What this could lead to
If triple therapy works better, it could offer a more effective way to lower cholesterol in people with diabetes, reducing heart disease risk.
What could go wrong
This is a small, short-term study (12 weeks) with only 126 participants. Results may not apply to everyone, and adding a third drug could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

126 people

The number who actually took part.

Started

Jan 2026

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females * Age 35-60 years * HbA1c ≥ 7.0 (≥ 48 mmol/mol) * On stable anti-diabetic therapy for at least 3 months * LDL-C \> 100 mg/dL on at least two occasions * Diagnosed with hypercholesterolemia * Establish high cardiovascular risk (e.g, previous MI, stroke or atherosclerosis) or * ≥2 cardiovascular risk factors (hypertension, smoking, obesity, family history) * BMI \>23 - \<32(WHO Asian Criteria) * No prior statin side effects Exclusion Criteria: * HbA1c \>10 % (86 mmol/mol) * BMI \> 32 * Type 1 Diabetes, gestational diabetes * Pregnancy or lactation * Acute liver disease or ALT/AST levels \> 3× the upper limit of normal * Renal failure (GFR \< 30 mL/min) * Uncontrolled hypothyroidism or nephrotic syndrome * Recent cancer diagnosis (last 6 months) * Current use of other lipid-lowering agents (e.g., fibrates or PCSK9 inhibitors) * Known allergy to any component * Statin intolerance with severe adverse effects (e.g., rhabdomyolysis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypercholesterolemia / elevated LDL cholesterol are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyslipidemias Hypercholesterolemia Hyperlipoproteinemia Type II type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypercholesterolemia / elevated LDL cholesterol Type 2 diabetes mellitus

Contacts and locations

Locations

  • National Medical Center

    Karachi, Sindh, 75500, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.